These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2111126)

  • 41. Immunostimulatory properties and antitumor activities of glucans (Review).
    Vannucci L; Krizan J; Sima P; Stakheev D; Caja F; Rajsiglova L; Horak V; Saieh M
    Int J Oncol; 2013 Aug; 43(2):357-64. PubMed ID: 23739801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of animal and human hematopoiesis by β-glucans: a review.
    Hofer M; Pospíšil M
    Molecules; 2011 Sep; 16(9):7969-79. PubMed ID: 21921869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes.
    Bergendiova K; Tibenska E; Majtan J
    Eur J Appl Physiol; 2011 Sep; 111(9):2033-40. PubMed ID: 21249381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overview of (1-->3)-beta-D-glucan immunobiology.
    Williams DL
    Mediators Inflamm; 1997; 6(4):247-50. PubMed ID: 18472852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody response in mice infected with Mesocestoides vogae (syn. Mesocestoides corti) tetrathyridia after treatment with praziquantel and liposomised glucan.
    Hrckova G; Velebný S; Kogan G
    Parasitol Res; 2007 May; 100(6):1351-9. PubMed ID: 17252273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beta-(1-->3)-D-glucan modulates DNA binding of nuclear factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1 receptor antagonist ratio.
    Luhm J; Langenkamp U; Hensel J; Frohn C; Brand JM; Hennig H; Rink L; Koritke P; Wittkopf N; Williams DL; Mueller A
    BMC Immunol; 2006 Mar; 7():5. PubMed ID: 16553947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The antioxidant effect of beta-Glucan on oxidative stress status in experimental spinal cord injury in rats.
    Kayali H; Ozdag MF; Kahraman S; Aydin A; Gonul E; Sayal A; Odabasi Z; Timurkaynak E
    Neurosurg Rev; 2005 Oct; 28(4):298-302. PubMed ID: 15864722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function.
    Tzianabos AO
    Clin Microbiol Rev; 2000 Oct; 13(4):523-33. PubMed ID: 11023954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.
    Vallespi MG; Glaria LA; Reyes O; Garay HE; Ferrero J; Araña MJ
    Clin Diagn Lab Immunol; 2000 Jul; 7(4):669-75. PubMed ID: 10882670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impairment of pulmonary macrophage function with total parenteral nutrition.
    Shou J; Lappin J; Daly JM
    Ann Surg; 1994 Mar; 219(3):291-7. PubMed ID: 8147610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.
    Babineau TJ; Marcello P; Swails W; Kenler A; Bistrian B; Forse RA
    Ann Surg; 1994 Nov; 220(5):601-9. PubMed ID: 7979607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunomodulatory therapy with thymopentin and indomethacin. Successful restoration of interleukin-2 synthesis in patients undergoing major surgery.
    Faist E; Markewitz A; Fuchs D; Lang S; Zarius S; Schildberg FW; Wachter H; Reichart B
    Ann Surg; 1991 Sep; 214(3):264-73; discussion 274-5. PubMed ID: 1929608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients.
    Spolarics Z; Siddiqi M; Siegel JH; Garcia ZC; Stein DS; Denny T; Deitch EA
    Crit Care Med; 2003 Jun; 31(6):1722-9. PubMed ID: 12794411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of enhanced macrophage function on early wound healing.
    Browder W; Williams D; Lucore P; Pretus H; Jones E; McNamee R
    Surgery; 1988 Aug; 104(2):224-30. PubMed ID: 3261048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A systematic review of randomized controlled trials exploring the effect of immunomodulative interventions on infection, organ failure, and mortality in trauma patients.
    Spruijt NE; Visser T; Leenen LP
    Crit Care; 2010; 14(4):R150. PubMed ID: 20687920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beneficial effect of enhanced macrophage function in the trauma patient.
    Browder W; Williams D; Pretus H; Olivero G; Enrichens F; Mao P; Franchello A
    Ann Surg; 1990 May; 211(5):605-12; discussion 612-3. PubMed ID: 2111126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunological status of septic and trauma patients. I. High tumor necrosis factor alpha serum levels in septic and trauma patients are not responsible for increased mortality; a prognostic value of serum interleukin 6.
    Adamik B; Zimecki M; Właszczyk A; Kübler A
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):169-75. PubMed ID: 9597083
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.